-
1دورية أكاديمية
المؤلفون: Chanchlani, Neil, Lin, Simeng, Chee, Desmond, Hamilton, Benjamin, Nice, Rachel, Arkir, Zehra, Bewshea, Claire, Cipriano, Bessie, Derikx, Lauranne A. A. P., Dunlop, Allan, Greathead, Louise, Griffiths, Rachel L., Ibraheim, Hajir, Kelleher, Peter, Kok, Klaartje B., Lees, Charlie W., MacDonald, Jonathan, Sebastian, Shaji, Smith, Philip J., McDonald, Timothy J., Irving, Peter M., Powell, Nick, Kennedy, Nicholas A., Goodhand, James R., Ahmad, Tariq
المصدر: Chanchlani , N , Lin , S , Chee , D , Hamilton , B , Nice , R , Arkir , Z , Bewshea , C , Cipriano , B , Derikx , L A A P , Dunlop , A , Greathead , L , Griffiths , R L , Ibraheim , H , Kelleher , P , Kok , K B , Lees , C W , MacDonald , J , Sebastian , S , Smith , P J , McDonald , T J , Irving , P M , Powell , N , Kennedy , ....
مصطلحات موضوعية: adalimumab, biologic, CLARITY, COVID-19, immunosuppression, inflammatory bowel disease, infliximab, vaccination, vedolizumab
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1093/ecco-jcc/jjab153Test
https://kclpure.kcl.ac.uk/portal/en/publications/1fd256f3-70ad-4c8d-b7f5-eed520031c42Test
https://kclpure.kcl.ac.uk/ws/files/170412073/Adalimumab_and_Infliximab_Impair_CHANCHLANI_Published_online_2_Sept_21_GOLD_VoR_CC_BY_NC_.pdfTest
http://www.scopus.com/inward/record.url?scp=85126490511&partnerID=8YFLogxKTest -
2دورية أكاديمية
المؤلفون: Langford, Thomas, Arkir, Zehra, Chalkidou, Anastasia, Goddard, Kate, Kaftantzi, Lamprini, Samaan, Mark, Irving, Peter
المصدر: Langford , T , Arkir , Z , Chalkidou , A , Goddard , K , Kaftantzi , L , Samaan , M & Irving , P 2018 , ' The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients : Protocol for a Validation Study ' , JMIR research protocols , vol. 7 , no. 10 , e11218 . https://doi.org/10.2196/11218Test
مصطلحات موضوعية: Anti-TNF, Antidrug antibodies, Crohn’s disease, ELISA, Inflammatory bowel disease, Infliximab, Therapeutic drug monitoring
الإتاحة: https://doi.org/10.2196/11218Test
https://kclpure.kcl.ac.uk/portal/en/publications/da913e35-9410-407e-8b94-10d74230cbffTest
http://www.scopus.com/inward/record.url?scp=85102368064&partnerID=8YFLogxKTest -
3
المؤلفون: Claire Bewshea, James R Goodhand, Peter Kelleher, Nick Powell, Rachel L Griffiths, Nicholas A. Kennedy, Philip J Smith, Shaji Sebastian, Arkir Zehra, Bessie Cipriano, Desmond Chee, Louise Greathead, Benjamin Hamilton, Simeng Lin, Rachel Nice, Lauranne A A P Derikx, Neil Chanchlani, Hajir Ibraheim, Peter M. Irving, Klaartje Kok, Charlie W. Lees, Jonathan Macdonald, Timothy J. McDonald, Allan Dunlop, Tariq Ahmad
المصدر: Journal of Crohn's and Colitis, 16, 3, pp. 389-397
Journal of Crohn's & Colitis
Journal of Crohn's and Colitis, 16, 389-397
Chanchlani, N, Lin, S, Chee, D, Hamilton, B, Nice, R, Arkir, Z, Bewshea, C, Cipriano, B, Derikx, L A A P, Dunlop, A, Greathead, L, Griffiths, R L, Ibraheim, H, Kelleher, P, Kok, K B, Lees, C W, MacDonald, J, Sebastian, S, Smith, P J, McDonald, T J, Irving, P M, Powell, N, Kennedy, N A, Goodhand, J R & Ahmad, T 2022, ' Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses : Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients ', Journal of Crohn's & colitis, vol. 16, no. 3, pp. 389-397 . https://doi.org/10.1093/ecco-jcc/jjab153Testمصطلحات موضوعية: Male, TNF, Gastroenterology, Serology, Seroepidemiologic Studies, adalimumab, skin and connective tissue diseases, immunosuppression, biology, medicine.diagnostic_test, General Medicine, Eccojc/1020, Original Article, Drug Monitoring, Antibody, Life Sciences & Biomedicine, biologic, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], medicine.drug, vedolizumab, Adult, medicine.medical_specialty, Combination therapy, MATURATION, Vedolizumab, DEFICIENT, inflammatory bowel disease, Internal medicine, Adalimumab, medicine, Humans, Seroprevalence, AcademicSubjects/MED00260, Biological Products, Science & Technology, Gastroenterology & Hepatology, SARS-CoV-2, business.industry, COVID-19, 1103 Clinical Sciences, vaccination, Inflammatory Bowel Diseases, Infliximab, ALPHA, Therapeutic drug monitoring, CLARITY, Antibody Formation, biology.protein, Tumor Necrosis Factor Inhibitors, infliximab, business, INFLAMMATORY-BOWEL-DISEASE
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c08447d7329ab51228946a10f8ee899Test
-
4دورية أكاديمية
المؤلفون: Chanchlani, Neil, Lin, Simeng, Chee, Desmond, Hamilton, Benjamin, Nice, Rachel, Arkir, Zehra, Bewshea, Claire, Cipriano, Bessie, Derikx, Lauranne A A P, Dunlop, Allan, Greathead, Louise, Griffiths, Rachel L, Ibraheim, Hajir, Kelleher, Peter, Kok, Klaartje B, Lees, Charlie W, MacDonald, Jonathan, Sebastian, Shaji, Smith, Philip J, McDonald, Timothy J
المصدر: Journal of Crohn's & Colitis; Mar2022, Vol. 16 Issue 3, p389-397, 9p
-
5
المؤلفون: Langford, Thomas, Arkir, Zehra, Chalkidou, Anastasia, Goddard, Kate, Kaftantzi, Lamprini, Samaan, Mark, Irving, Peter
المصدر: JMIR Research Protocols
مصطلحات موضوعية: Crohn’s disease, medicine.medical_specialty, Cost effectiveness, therapeutic drug monitoring, Disease, Inflammatory bowel disease, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), inflammatory bowel disease, Protocol, medicine, antidrug antibodies, 030212 general & internal medicine, Intensive care medicine, Protocol (science), Crohn's disease, medicine.diagnostic_test, business.industry, anti-TNF, General Medicine, medicine.disease, Infliximab, 3. Good health, Therapeutic drug monitoring, ELISA, 030211 gastroenterology & hepatology, infliximab, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fec5304268af32ac8b8dfcdbac0ca896Test
https://doi.org/10.2196/11218Test